Molecular mechanisms of pharmacological doses of ascorbate on cancer cells
Authors:
- 12 June 2015
- journal article
- research article
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 165 (11-12) , 251-257
Abstract
Intravenous application of high-dose ascorbate (vitamin C) has been used in complementary medicine since the 1970s to treat cancer patients. In recent years it became evident that high-dose ascorbate in the millimolar range bears selective cytotoxic effects on cancer cells in vitro and in vivo. This anticancer effect is dose dependent, catalyzed by serum components and mediated by reactive oxygen species and ascorbyl radicals, making ascorbate a pro-oxidative pro-drug that catalyzes hydrogen peroxide production in tissues instead of acting as a radical scavenger. It further depends on HIF-1 signaling and oxygen pressure, and shows a strong epigenetic signature (alteration of DNA-methylation and induction of tumor-suppressing microRNAs in cancer cells). The detailed understanding of ascorbate-induced antiproliferative molecular mechanisms warrants in-depth preclinical evaluation in cancer-bearing animal models for the optimization of an efficacious therapy regimen (e.g., combination with hyperbaric oxygen or O2-sensitizers) that subsequently need to be evaluated in clinical trials. Die intravenöse Hochdosis-Vitamin C Therapie wird seit über 30 Jahren in der Komplementärmedizin als unterstützende Behandlung von Krebspatienten angewendet. Pharmakologische Dosen von Vitamin C im Millimolarbereich wirken in vitro und in vivo selektiv toxisch auf Krebszellen. Diese Krebszellen-tötenden Eigenschaften werden durch Serumkomponenten katalysiert und durch H2O2 und Ascorbyl-Radikale vermittelt, so dass Vitamin C dosisabhängig im Tumorgewebe als pro-oxidatives Molekül fungiert und nicht als Radikalfänger. Weiterhin werden die pharmakologischen Eigenschaften von Vitamin C durch die HIF-1 Signaltransduktionskaskade und den O2-Partialdruck maßgeblich beeinflusst und wirken zusätzlich auf epigenetischer Ebene über Modifizierung der DNA-Methylierung und Induktion von Tumor-supprimierenden microRNAs. Aus dem heutigen Verständnis des komplexen molekularen Wirkmechanismus von Vitamin C gegenüber Krebszellen erschließt sich die Notwendigkeit der Optimierung des Therapieschemas in geeigneten Tiermodellen (z. B. in Kombination mit hyperbarer Sauerstofftherapie oder gewebegängigen O2-Liberatoren), um die rasche Übertragung einer effektiven Hochdosis-Vitamin C Therapie für Krebspatienten in die Klinik zu ermöglichen.Keywords
This publication has 71 references indexed in Scilit:
- Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2013
- Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patientsJournal of Translational Medicine, 2013
- MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data setsCell Death & Differentiation, 2012
- Hyperbaric oxygen therapy and cancer—a reviewTargeted Oncology, 2012
- Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radical Biology and Medicine, 2011
- Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cellsMolecular Nutrition & Food Research, 2011
- Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic CancerClinical Cancer Research, 2010
- Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProceedings of the National Academy of Sciences, 2008
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProceedings of the National Academy of Sciences, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002